Hirsh, J.; Weitz, J. I. New antithrombotic agents. Lancet 1999, 353, 1431-1436.
Hirsh, J.; Weitz, J. I. Thrombosis and anticoagulation. Semin. Hematol. 1999, 36, 118-132.
Thiagarajan, P.; Wu, K. K. Mechanisms of antithrombotic drugs. Adv. Pharmacol. 1999, 46, 297-324.
Dahlback, B. Blood coagulation. Lancet 2000, 355, 1627-1632.
Davie, E. W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30, 10363-10370.
Davie, E. W. Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemostasis 1995, 74, 1-6.
Mann, K. G. Biochemistry and physiology of blood coagulation. Thromb Haemostasis 1999, 82, 165-174.
Porcari, A. R.; Chi, L.; Leadley, R. Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors. Expert Opin. Invest. Drugs 2000, 9, 1595-1600.
Tan, K. T.; Makin, A.; Lip, G. Y. Factor X inhibitors. Expert Opin. Invest. Drugs 2003, 12, 799-804.
Gould, W. R.; Leadley, R. J. Recent advances in the discovery and development of direct coagulation factor xa inhibitors. Curr. Pharm. Des. 2003, 9, 2337-2347.
Hirsh, J.; Warkentin, T. E.; Shaughnessy, S. G.; Anand, S. S.; Halperin, J. L.; Raschke, R.; Granger, C.; Ohman, E. M.; Dalen, J. E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001, 119, 64S-94S.
Hirsh, J.; Dalen, J.; Anderson, D. R.; Poller, L.; Bussey, H.; Ansell, J.; Deykin, D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119, 8S-21S.
Vacca, J. P. New advances in the discovery of thrombin and factor Xa inhibitors. Curr. Opin. Chem. Biol. 2000, 4, 394-400.
Sanderson, P. E. Anticoagulants: Inhibitors of thrombin and factor Xa. Annu. Rep. Med. Chem. 2001, 36, 79-88.
Kikumoto, R.; Tamao, Y.; Tezuka, T.; Tonomura, S.; Hara, H.; Ninomiya, K.; Hijikata, A.; Okamoto, S. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-1-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984, 23, 85-90.
Sturzebecher, J.; Markwardt, F.; Voigt, B.; Wagner, G.; Walsmann, P. Cyclic amides of N-alpha-arylsulfonylaminoacylated 4-amidinophenylalanine. Tight binding inhibitors of thrombin. Thromb. Res. 1983, 29, 635-642.
Eriksson, U. G.; Renberg, L.; Bredberg, U.; Teger-Nilsson, A. C.; Regardh, C. G. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm. Drug Dispos. 1998, 19, 55-64.
Eriksson, B. I.; Carlsson, S.; Halvarsson, M.; Risberg, B.; Mattsson, C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb. Haemostasis 1997, 78, 1404-1407.
Hilpert, K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadvary, P.; Labler, L.; Muller, K.; Schmid, G.; Tschopp, T. B.; et al. Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 1994, 37, 3889-3901.
Kettner, C.; Shaw, E. D-Phe-Pro-ArgCH2Cl-A selective affinity label for thrombin. Thromb. Res. 1979, 14, 969-973.
Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi, M.; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J. Med. Chem. 1990, 33, 1729-1735.
Neises, B.; Broersma, R. J.; Tarnus, C.; Piriou, F.; Remy, J. M.; Lintz, C.; Heminger, E. F.; Kutcher, L. W. Synthesis and comparison of tripeptidylfluoroalkane thrombin inhibitors. Bioorg. Med. Chem. 1995, 3, 1049-1061.
Iwanowicz, E. J.; Lau, W. F.; Lin, J.; Roberts, D. G.; Seiler, S. M. Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling. J. Med. Chem. 1994, 37, 2122-2124.
Boatman, P. D.; Ogbu, C. O.; Eguchi, M.; Kim, H. O.; Nakanishi, H.; Cao, B.; Shea, J. P.; Kahn, M. Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors. J. Med. Chem. 1999, 42, 1367-1375.
Li, M.; Lin, Z.; Johnson, M. E. Structure-based design and synthesis of novel thrombin inhibitors based on phosphinic peptide mimetics. Bioorg. Med. Chem. Lett. 1999, 9, 1957-1962.
Kettner, C.; Mersinger, L.; Knabb, R. The selective inhibition of thrombin by peptides of boroarginine. J. Biol. Chem. 1990, 265, 18289-18297.
Tamura, S. Y.; Levy, O. E.; Uong, T. H.; Reiner, J. E.; Goldman, E. A.; Ho, J. Z.; Cohen, C. R.; Bergum, P. W.; Nutt, R. F.; Brunck, T. K.; Semple, J. E. Guanylpiperidine peptidomimetics: potent and selective bis-cation inhibitors of factor Xa. Bioorg. Med. Chem. Lett. 2000, 10, 745-749.
Marlowe, C. K.; Sinha, U.; Gunn, A. C.; Scarborough, R. M. Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: structures based on the (D)-Arg-Gly-Arg tripeptide sequence. Bioorg. Med. Chem. Lett. 2000, 10, 13-16.
Hara, T.; Yokoyama, A.; Ishihara, H.; Yokoyama, Y.; Nagahara, T.; Iwamoto, M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb. Haemostasis 1994, 71, 314-319.
Adler, M.; Davey, D. D.; Phillips, G. B.; Kim, S. H.; Jancarik, J.; Rumennik, G.; Light, D. R.; Whitlow, M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry 2000, 39, 12534-12542.
Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41, 3210-3219.
Lumma, W. C., Jr.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J. Med. Chem. 1998, 41, 1011-1013.
Scozzafava, A.; Briganti, F.; Supuran, C. T. Protease inhibitors. Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium- sulfanilylguanidine moieties at the P1 site. Eur. J. Med. Chem. 1999, 34, 939-952.
Clare, B. W.; Scozzafava, A.; Supuran, C. T. Protease inhibitors, part 13: Specific, weakly basic thrombin inhibitors incorporating sulfonyl dicyandiamide moieties in their structure. J. Enzyme Inhib. 2001, 16, 1-13.
Sanderson, P. E.; Stanton, M. G.; Dorsey, B. D.; Lyle, T. A.; McDonough, C.; Sanders, W. M.; Savage, K. L.; Naylor-Olsen, A. M.; Krueger, J. A.; Lewis, S. D.; Lucas, B. J.; Lynch, J. J.; Yan, Y. Azaindoles: moderately basic Pl groups for enhancing the selectivity of thrombin inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 795-798.
Pochet, L.; Doucet, C.; Schynts, M.; Thierry, N.; Boggetto, N.; Pirotte, B.; Jiang, K. Y.; Masereel, B.; de Tullio, P.; Delarge, J.; Reboud-Ravaux, M. Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of α-chymotrypsin: significance of the "aromatic" nature of the novel ester-type coumarin for strong inhibitory activity. J. Med. Chem. 1996, 39, 2579-2585.
Doucet, C.; Pochet, L.; Thierry, N.; Pirotte, B.; Delarge, J.; Reboud-Ravaux, M. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J. Med. Chem. 1999, 42, 4161-4171.
Pochet, L.; Doucet, C.; Dive, G.; Wouters, J.; Masereel, B.; Reboud-Ravaux, M.; Pirotte, B. Coumarinic derivatives as mechanism-based inhibitors of alpha-chymotrypsin and human leukocyte elastase. Bioorg. Med. Chem. 2000, 8, 1489-1501.
Pochet, L.; Frederick, R.; Masereel, B. Coumarin and isocoumarin as serine protease inhibitors. Curr. Pharm. Des. 2004, 10, 3781-3796.
Kam, C. M.; Fujikawa, K.; Powers, J. C. Mechanism-based isocoumarin inhibitors for trypsin and blood coagulation serine proteases: new anticoagulants. Biochemistry 1988, 27, 2547-2557.
Kam, C. M.; Kerrigan, J. E.; Plaskon, R. R.; Duffy, E. J.; Lollar, P.; Suddath, F. L.; Powers, J. C. Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases. Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy)isocoumarins on inhibitory and anticoagulant potency. J. Med. Chem. 1994, 37, 1298-1306.
Iranpoor, N.; Firouzabadi, H.; Aghapour, G.; Vaez Zadeh, A. R. Triphenylphosphine/2,3-dichloro-5,6-dicyanobenzoquinone as a new selective and neutral system for the facile conversion of alcohols, thiols and selenols to alkyl halide in the presence of halide ions. Tetrahedron 2002, 58, 8689-8693.
Wouters, J.; Huygens, M.; Pochet, L.; Pirotte, B.; Durand, F.; Masereel, B. Structural approach of the mechanism of inhibition of a-chymotrypsin by coumarins. Bioorg. Chem. Lett. 2002, 12, 1109-1112.
Pochet, L.; Dieu, M.; Frédérick, R.; Murray, A. M.; Kempen, I.; Pirotte, B.; Masereel, B. Investigation of the inhibition mechanism of coumarins on chymotrypsin by mass spectrometry. Tetrahedron 2003, 59, 4557-4561.
Silverman, R. B. Mechanism-based enzyme inactivators. Methods Enzymol. 1995, 249, 240-283.
Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
Discover3, version 2.98; Accelrys Inc.: San Diego, CA, 1998.
InsightII, version 2000; Accelrys Inc.: San Diego, CA, 2000.
Cruciani, G.; Pastor, M.; Clementi, S. Handling Information from 3D Grid Maps for QSAR Studies. Molecular Modeling and Prediction of Bioactivity; Kluwer Academic/Plenum Publishers: New York, 2000; pp 73-82.
Cruciani, G.; Crivori, P.; Carrupt, P.-A.; Testa, B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct: THEOCHEM 2000, 503, 17-30.
Crivori, P.; Cruciani, G.; Carrupt, P. A.; Testa, B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 2000, 43, 2204-2216.
URL: http://www.moldiscovery.com.
Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A., Jr.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; Replogle, E. S.; Pople, J. A. Gaussian 98, revision A.11; Gaussian, Inc.: Pittsburgh, PA, 1998.
